ZEOX · Zeo ScientifiX, Inc.
Market Cap
$10.11M
Shares
7.84M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$5.2M
+12.5%
FY2025
Net Income
-$5.52M
-17.3%
FY2025
Gross Margin
82.09%
+0.4pp
FY2025
Operating Margin
-103.6%
+11.5pp
FY2025
Diluted EPS
-$0.86
-16.2%
FY2025
Operating Cash Flow
-$718K
+50.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $6.99M | $5.2M | $4.62M | $4.56M | $6.49M | $5.6M | $3.06M | $1.7M | $964.53K | $569.85K | $184.88K | $147.63K | $49.2K | $82.97K | $87.15K | $18.08K | |
| — | — | — | — | — | -$37.93K | -$177.74K | — | — | — | — | — | — | — | — | — | |
| $1.29M | $931K | $844K | $508K | $753.53K | $547.88K | $398.61K | $300.84K | $209.3K | $160.63K | $94.4K | $49.41K | $20.06K | $44.44K | $61.12K | $10.99K | |
| $5.7M | $4.27M | $3.78M | $4.05M | $5.74M | $5.05M | $2.66M | $1.4M | $755.23K | $409.22K | $90.48K | $98.22K | $29.14K | $38.53K | $26.03K | $7086 | |
| — | 82.09% | 81.73% | 88.85% | 88.39% | 90.21% | 86.96% | 82.33% | 78.3% | 71.81% | 48.94% | 66.53% | 59.23% | 46.44% | 29.87% | 39.19% | |
| — | $100K | $164K | $922.7K | $791.3K | $1.12M | $233.53K | $54.86K | — | — | — | — | — | — | — | — | |
| $9.83M | $9.65M | $9.1M | $10.82M | $14.58M | $17.79M | $15.1M | $3.18M | $4.25M | $9.05M | $1.13M | $842.53K | $94.96K | $43.65K | $14.48K | $5572 | |
| $77K | $73K | $74K | $486K | $332.51K | $52.7K | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | $9.05M | $1.13M | — | $94.96K | $70.7K | $38.37K | $18.81K | |
| -$4.13M | -$5.39M | -$5.32M | -$6.77M | -$8.84M | -$12.74M | -$12.44M | -$1.78M | -$3.49M | -$8.64M | -$1.04M | -$744.31K | — | — | — | — | |
| — | -103.6% | -115.13% | -148.49% | -136.23% | -227.68% | -407.03% | -104.36% | -361.85% | -1516.47% | -564.32% | -504.18% | — | — | — | — | |
| -$4.05M | -$5.31M | -$5.25M | -$6.28M | -$8.51M | -$12.69M | — | — | — | — | — | — | — | — | — | — | |
| $76K | $98K | $92K | $431K | $398.26K | $37.93K | $177.74K | $46.6K | $228.33K | $576.02K | $12.73K | — | — | — | — | — | |
| -$146K | -$136K | $613K | -$10K | $249.5K | $25.48K | $32.72K | $84.79K | $21.43K | $9050 | $0 | — | — | — | — | — | |
| -$9.49M | — | — | — | -$8.9M | -$12.76M | -$12.58M | -$1.74M | -$3.43M | -$9.11M | — | — | — | — | — | — | |
| — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 | — | — | — | — | — | |
| -$3.88M | -$5.52M | -$4.71M | -$6.99M | -$8.9M | -$12.76M | -$12.58M | -$1.74M | -$3.46M | -$8.97M | -$1.25M | -$738.35K | -$65.82K | -$32.18K | -$13.34K | -$11.73K | |
| — | -106.19% | -101.84% | -153.29% | -137.06% | -227.9% | -411.78% | -102.06% | -358.95% | -1574.49% | -677.84% | -500.14% | -133.78% | -38.78% | -15.3% | -64.85% | |
| — | — | — | — | — | — | $0 | -$978 | $30.75K | -$140.39K | $0 | — | — | — | — | — | |
| USD/shares | -$0.58 | -$0.86 | -$0.74 | -$0.99 | -$1.56 | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | -$0.58 | -$0.86 | -$0.74 | -$0.99 | -$1.56 | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 6.41M | 6.34M | 7.03M | 5.69M | 5.3M | 3.35M | 2.33M | 1.36M | 542.98K | 501.89K | 670.24K | 750.6K | 39.85K | 37.5K | 7807.205 |
| shares | — | 6.41M | 6.34M | 7.03M | 5.69M | 5.3M | 3.35M | 2.33M | 1.36M | 542.98K | 501.89K | 670.24K | 750.6K | 39.85K | 37.5K | 7807.205 |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.23×
EV/EBIT
—
P/E (TTM)
—
Peer median 2.91×
Peer medians compare against the 194 similar-size Biotechnology companies (of 513 listed).